A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : AA / abiraterone

[Related PubMed/MEDLINE]
Total Number of Papers: 13
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   AA  (>> Co-occurring Abbreviation)
Long Form:   abiraterone
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. AR, ARFL, CRPC, CTC, PBMC, PFS
2019 Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience. ENZ, mCRPC, OS, PFS, PSA
2019 Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naive prostate cancer. ADT, DCT, PF-QALYs
2019 Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort. EZ, mCPRC, PFS
2018 Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer. AA-ENZA, ENZA, PFS, PSA
2018 Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. DP, mCRPC, OS, rPFS, SII
2017 Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status. AR, CRPC, ER, ONA, PR, pts
2017 Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone. mCRPC, OS, PNI, rPFS
2017 Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone. mCRPC, OS, rPFS
10  2016 Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. CRPC, mCRPC, OS, PFS
11  2014 Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. bPFS, KT, mCRPC, OS, PSA-RR
12  2014 Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer. MCRPC
13  2013 Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel. CBZ, CRPC, ENZ